Candidate Parkinson’s Drug Advances to Phase 3 Trial
The Michael J Fox Foundation has reported today, 1st September 2015, that researchers testing the compound inosine for its effect on Parkinson’s progression have funding from the National Institutes of…
Low-dose lithium may reduce dyskinesia
Science Daily reports a new study which claims that low-dose lithium reduced involuntary motor movements or dyskinesia — the troubling side effect of the medication most commonly used to treat…
Monoclonal antibodies may provide effective treatment
Science Daily reports that a team led by Fernando Goni, PhD, an adjunct associate professor of Neurology, and Thomas Wisniewski MD, director of the Center for Cognitive Neurology at NYU…
α-Synuclein strains cause distinct synucleinopathies
Misfolded protein aggregates represent a continuum with overlapping features in neurodegenerative diseases, but differences in protein components and affected brain regions. The molecular hallmark of synucleinopathies such as Parkinson’s disease,…
Placebo effect matters
Science Daily reports that learning-related brain activity in Parkinson’s patients improves as much in response to a placebo treatment as to real medication, according to a new study by researchers…
Trials of Parkinson’s vaccine show promise
The Michael J Fox Foundation reports that results from the first clinical trial of a new vaccine for Parkinson’s suggest the treatment is safe and should go forward to be…
- « Previous Page
- 1
- ...
- 9
- 10
- 11
- 12
- 13
- ...
- 20
- ...
- 23
- Next Page »